03AUG20 Fluorescent Imaging immunofluorescence of cancer cells growing in 2D with nuclei in blue, cytoplasm in red and DNA damage foci in greeN
Clinical Capabilities

Clinical Diagnostic Services

Over two decades of clinical laboratory experience

Under the guidance of a quality control (QC) manager and supervising physician, our clinical laboratory technicians have worked with over 300 medical institutions throughout Japan and many hundreds more in the USA, India, and Europe. Our screening tests offer superior accuracy and efficacy compared to standard methods of diagnosis.

 

PRENITA Reproductive Health

We offer a range of prenatal and postnatal screening tests that provide clinicians with accurate results with actionable insights. Our PRENITA Reproductive Health services include the following diagnostic tests:

  • Preimplantation Genetic Screening/Diagnosis (PGS/PGD)
  • Non-Invasive Prenatal Screening Test (NIPT)
  • Invasive Diagnostic Testing
  • Carrier Screening

Learn more about PRENITA on the Bioserve website →

Oncology 

Our pharmacogenomics assays can help clinicians to make better decisions about treatment choices and prescribing. These integrated molecular diagnostic solutions can assist at every stage of the cancer journey:

  • Hereditary risk assessment
  • Diagnosis and Prognosis
  • Treatment selection and monitoring
  • Disease surveillance

Explore oncology services on the Bioserve website →

HLA Typing

As experts in human tissue research, we offer a comprehensive range of diagnostic tests that can screen for the presence of donor-specific antibodies (DSA) before or after transplantaition. We use up to four different diagnostic tests in our HLA typing service:

  • Flowcytometric crossmatching (FCXM)
  • Anti-HLA antibody screening and  single antigen identification (Class I & II)
  • HLA typing

Learn more about HLA Typing services →

COVID PCR Testing

In 2021 we launched a high throughput Covid-19 identification service to contribute to the end of the pandemic. This PCR-based method uses SmartAmp and Allplex screening to identify coronavirus variants. The Allplex system can simultaneously detect:

  • HV69/70 del mutation found in the UK variant
  • E484K found in the South African and Brazilian variants
  • N501Y found in all three novel variants

Read the official Press Release →

REPROCELL will participate at

BioPharm America 2021 conference

20 – 23 Sept, 2021 / Virtual Meeting